Aurobindo Pharma has acquired a 26% equity stake in Swarnaakshu Solar Power Private Limited for an initial investment of Rs 52 lakhs. The pharmaceutical company also executed a solar power purchase agreement with the entity to procure solar power for captive consumption. This strategic move aligns with the captive power policy of the Government of Telangana.

The Board had previously approved an investment of up to Rs 10.40 crores to acquire 26% of the paid-up equity share capital and other securities of Swarnaakshu. Following the initial disbursement on June 25, 2026, the balance investment will be made periodically depending on the progress of the solar project and the fund requirements of the investee company.

The transaction follows a series of disclosures made by the company starting February 6, 2025, regarding the proposed agreement and investment. The completion of the stake acquisition and the signing of the power purchase agreement mark the finalization of this initiative to enhance sustainable energy usage for the company's operations.

Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma, has received approval from the U.S. Federal Trade Commission (FTC) to acquire Lannett Company LLC. The transaction is valued at $250 million on a cash-free, debt-free basis and includes normalized working capital. The deal is expected to close before the end of June 2026.

Transaction Details

The acquisition involves purchasing 100% of the membership interest in Lannett Company LLC. Lannett is a Pennsylvania-based generic pharmaceutical company specializing in complex, non-opioid controlled substances. The following table outlines the key entities involved in the deal:

Strategic Benefits

The acquisition will add a U.S.-based manufacturing facility in Seymour, Indiana, to Aurobindo USA's network. This site has the capacity to scale production to approximately 4 billion doses annually. The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share and generate cost efficiencies and SG&A synergies.

Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, stated that the acquisition accelerates revenue growth and strengthens U.S.-based manufacturing capabilities. Tim Crew, Chief Executive Officer of Lannett Company, expressed confidence that Aurobindo's market reach will make their portfolio of medicines more affordable and accessible.